nodes	percent_of_prediction	percent_of_DWPC	metapath
Tenofovir—NME2—ovarian cancer	0.566	1	CbGaD
Tenofovir—ABCC10—Paclitaxel—ovarian cancer	0.0869	0.315	CbGbCtD
Tenofovir—ABCC10—Docetaxel—ovarian cancer	0.0628	0.228	CbGbCtD
Tenofovir—ABCC10—Doxorubicin—ovarian cancer	0.0468	0.17	CbGbCtD
Tenofovir—ABCC2—Paclitaxel—ovarian cancer	0.0248	0.0899	CbGbCtD
Tenofovir—ABCC2—Carboplatin—ovarian cancer	0.0234	0.0847	CbGbCtD
Tenofovir—ABCC2—Docetaxel—ovarian cancer	0.018	0.065	CbGbCtD
Tenofovir—ABCC2—Doxorubicin—ovarian cancer	0.0134	0.0485	CbGbCtD
Tenofovir—Adefovir Dipivoxil—NME2—ovarian cancer	0.00387	0.918	CrCbGaD
Tenofovir—AK4—Irinotecan—Topotecan—ovarian cancer	0.00318	1	CbGdCrCtD
Tenofovir—AK2—myometrium—ovarian cancer	0.00238	0.0514	CbGeAlD
Tenofovir—NME1-NME2—female reproductive system—ovarian cancer	0.00183	0.0396	CbGeAlD
Tenofovir—AK4—myometrium—ovarian cancer	0.00176	0.038	CbGeAlD
Tenofovir—NME2—embryo—ovarian cancer	0.00165	0.0358	CbGeAlD
Tenofovir—AK2—uterus—ovarian cancer	0.00154	0.0334	CbGeAlD
Tenofovir—AK4—uterine cervix—ovarian cancer	0.00137	0.0296	CbGeAlD
Tenofovir—NME2—epithelium—ovarian cancer	0.00135	0.0292	CbGeAlD
Tenofovir—AK2—bone marrow—ovarian cancer	0.00131	0.0283	CbGeAlD
Tenofovir—AK4—decidua—ovarian cancer	0.0013	0.0282	CbGeAlD
Tenofovir—AK2—female gonad—ovarian cancer	0.00126	0.0273	CbGeAlD
Tenofovir—AK2—vagina—ovarian cancer	0.00125	0.0271	CbGeAlD
Tenofovir—AK4—endometrium—ovarian cancer	0.00124	0.0268	CbGeAlD
Tenofovir—NME1—uterus—ovarian cancer	0.00118	0.0256	CbGeAlD
Tenofovir—AK4—gonad—ovarian cancer	0.00115	0.0248	CbGeAlD
Tenofovir—AK4—uterus—ovarian cancer	0.00114	0.0247	CbGeAlD
Tenofovir—AK2—testis—ovarian cancer	0.00112	0.0242	CbGeAlD
Tenofovir—NME1-NME2—lymph node—ovarian cancer	0.00107	0.0231	CbGeAlD
Tenofovir—NME1—female reproductive system—ovarian cancer	0.00106	0.023	CbGeAlD
Tenofovir—AK4—female reproductive system—ovarian cancer	0.00102	0.0222	CbGeAlD
Tenofovir—NME1—bone marrow—ovarian cancer	0.001	0.0217	CbGeAlD
Tenofovir—NME2—female reproductive system—ovarian cancer	0.001	0.0217	CbGeAlD
Tenofovir—NME1—female gonad—ovarian cancer	0.000967	0.0209	CbGeAlD
Tenofovir—AK4—female gonad—ovarian cancer	0.000932	0.0202	CbGeAlD
Tenofovir—AK4—vagina—ovarian cancer	0.000926	0.0201	CbGeAlD
Tenofovir—NME2—female gonad—ovarian cancer	0.000911	0.0197	CbGeAlD
Tenofovir—NME1—testis—ovarian cancer	0.000858	0.0186	CbGeAlD
Tenofovir—ABCC10—myometrium—ovarian cancer	0.000833	0.018	CbGeAlD
Tenofovir—AK4—testis—ovarian cancer	0.000827	0.0179	CbGeAlD
Tenofovir—AK2—lymph node—ovarian cancer	0.00081	0.0175	CbGeAlD
Tenofovir—NME2—testis—ovarian cancer	0.000808	0.0175	CbGeAlD
Tenofovir—ABCC10—uterine cervix—ovarian cancer	0.000649	0.014	CbGeAlD
Tenofovir—NME1—lymph node—ovarian cancer	0.000622	0.0135	CbGeAlD
Tenofovir—ABCC10—decidua—ovarian cancer	0.000618	0.0134	CbGeAlD
Tenofovir—AK4—lymph node—ovarian cancer	0.000599	0.013	CbGeAlD
Tenofovir—ABCC10—endometrium—ovarian cancer	0.000587	0.0127	CbGeAlD
Tenofovir—NME2—lymph node—ovarian cancer	0.000586	0.0127	CbGeAlD
Tenofovir—ABCC10—gonad—ovarian cancer	0.000544	0.0118	CbGeAlD
Tenofovir—ABCC10—uterus—ovarian cancer	0.000541	0.0117	CbGeAlD
Tenofovir—ABCC10—female reproductive system—ovarian cancer	0.000486	0.0105	CbGeAlD
Tenofovir—ABCC10—bone marrow—ovarian cancer	0.000459	0.00993	CbGeAlD
Tenofovir—ABCC4—uterus—ovarian cancer	0.000448	0.00971	CbGeAlD
Tenofovir—ABCC10—female gonad—ovarian cancer	0.000442	0.00957	CbGeAlD
Tenofovir—ABCC10—vagina—ovarian cancer	0.00044	0.00952	CbGeAlD
Tenofovir—ABCC4—female reproductive system—ovarian cancer	0.000403	0.00873	CbGeAlD
Tenofovir—ABCC10—testis—ovarian cancer	0.000392	0.00849	CbGeAlD
Tenofovir—ABCC2—female reproductive system—ovarian cancer	0.00039	0.00845	CbGeAlD
Tenofovir—ABCC4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	0.000384	0.00883	CbGpPWpGaD
Tenofovir—ABCC4—bone marrow—ovarian cancer	0.000381	0.00824	CbGeAlD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—SLC2A1—ovarian cancer	0.00038	0.00874	CbGpPWpGaD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—CDH1—ovarian cancer	0.000373	0.00859	CbGpPWpGaD
Tenofovir—ABCC4—female gonad—ovarian cancer	0.000367	0.00794	CbGeAlD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—BIRC5—ovarian cancer	0.00035	0.00804	CbGpPWpGaD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—CCND2—ovarian cancer	0.000343	0.00788	CbGpPWpGaD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—MET—ovarian cancer	0.000342	0.00788	CbGpPWpGaD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—TERT—ovarian cancer	0.000339	0.00779	CbGpPWpGaD
Tenofovir—ABCC4—testis—ovarian cancer	0.000325	0.00704	CbGeAlD
Tenofovir—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	0.000324	0.00745	CbGpPWpGaD
Tenofovir—ABCC2—testis—ovarian cancer	0.000315	0.00682	CbGeAlD
Tenofovir—NME1—Arf6 trafficking events—CDH1—ovarian cancer	0.000302	0.00694	CbGpPWpGaD
Tenofovir—NME1—Nucleotide metabolism—TYMS—ovarian cancer	0.000298	0.00685	CbGpPWpGaD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—CDH1—ovarian cancer	0.000297	0.00682	CbGpPWpGaD
Tenofovir—Adenosine triphosphate—AKT1—ovarian cancer	0.000295	0.0699	CrCbGaD
Tenofovir—ABCC10—lymph node—ovarian cancer	0.000284	0.00616	CbGeAlD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—CCND1—ovarian cancer	0.000278	0.0064	CbGpPWpGaD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—CTNNB1—ovarian cancer	0.000276	0.00634	CbGpPWpGaD
Tenofovir—ABCC2—Irinotecan Pathway—APC—ovarian cancer	0.000273	0.00627	CbGpPWpGaD
Tenofovir—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00027	0.0062	CbGpPWpGaD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—BIRC5—ovarian cancer	0.000265	0.0061	CbGpPWpGaD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—TERT—ovarian cancer	0.000257	0.00591	CbGpPWpGaD
Tenofovir—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.000246	0.00565	CbGpPWpGaD
Tenofovir—ABCC4—lymph node—ovarian cancer	0.000236	0.00511	CbGeAlD
Tenofovir—ABCC2—lymph node—ovarian cancer	0.000228	0.00494	CbGeAlD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—CASP3—ovarian cancer	0.000227	0.00522	CbGpPWpGaD
Tenofovir—AK2—Metabolism—NME2—ovarian cancer	0.000227	0.00522	CbGpPWpGaD
Tenofovir—NME1—Arf6 trafficking events—CTNNB1—ovarian cancer	0.000223	0.00512	CbGpPWpGaD
Tenofovir—ABCC4—Fluoropyrimidine Activity—TYMS—ovarian cancer	0.000222	0.0051	CbGpPWpGaD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—CTNNB1—ovarian cancer	0.000219	0.00504	CbGpPWpGaD
Tenofovir—ABCC4—ABC-family proteins mediated transport—ABCB1—ovarian cancer	0.000211	0.00485	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000198	0.00454	CbGpPWpGaD
Tenofovir—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000195	0.00449	CbGpPWpGaD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—MMP9—ovarian cancer	0.00019	0.00437	CbGpPWpGaD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—PIK3CA—ovarian cancer	0.00019	0.00436	CbGpPWpGaD
Tenofovir—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000186	0.00428	CbGpPWpGaD
Tenofovir—CYP1A2—Estrogen Receptor Pathway—CYP1B1—ovarian cancer	0.000183	0.00421	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000181	0.00415	CbGpPWpGaD
Tenofovir—ABCC2—ABC-family proteins mediated transport—ABCB1—ovarian cancer	0.000178	0.00409	CbGpPWpGaD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—EGFR—ovarian cancer	0.000174	0.00399	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000169	0.00389	CbGpPWpGaD
Tenofovir—Skin disorder—Vinorelbine—ovarian cancer	0.000166	0.00275	CcSEcCtD
Tenofovir—ABCC4—Platelet degranulation—SPARC—ovarian cancer	0.000166	0.00381	CbGpPWpGaD
Tenofovir—Hypersensitivity—Chlorambucil—ovarian cancer	0.000165	0.00274	CcSEcCtD
Tenofovir—Gastrointestinal pain—Topotecan—ovarian cancer	0.000163	0.0027	CcSEcCtD
Tenofovir—Anorexia—Vinorelbine—ovarian cancer	0.000163	0.0027	CcSEcCtD
Tenofovir—Asthenia—Chlorambucil—ovarian cancer	0.000161	0.00266	CcSEcCtD
Tenofovir—Urinary tract disorder—Paclitaxel—ovarian cancer	0.00016	0.00264	CcSEcCtD
Tenofovir—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000159	0.00263	CcSEcCtD
Tenofovir—Pruritus—Chlorambucil—ovarian cancer	0.000159	0.00263	CcSEcCtD
Tenofovir—Urethral disorder—Paclitaxel—ovarian cancer	0.000158	0.00262	CcSEcCtD
Tenofovir—ABCC4—Response to elevated platelet cytosolic Ca2+—SPARC—ovarian cancer	0.000158	0.00363	CbGpPWpGaD
Tenofovir—Body temperature increased—Topotecan—ovarian cancer	0.000158	0.00261	CcSEcCtD
Tenofovir—Abdominal pain—Topotecan—ovarian cancer	0.000158	0.00261	CcSEcCtD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—MYC—ovarian cancer	0.000157	0.00361	CbGpPWpGaD
Tenofovir—ABCC10—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000157	0.00361	CbGpPWpGaD
Tenofovir—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000156	0.00258	CcSEcCtD
Tenofovir—Weight decreased—Docetaxel—ovarian cancer	0.000155	0.00256	CcSEcCtD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—AKT1—ovarian cancer	0.000155	0.00356	CbGpPWpGaD
Tenofovir—Pneumonia—Docetaxel—ovarian cancer	0.000154	0.00254	CcSEcCtD
Tenofovir—Diarrhoea—Chlorambucil—ovarian cancer	0.000153	0.00254	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000153	0.00352	CbGpPWpGaD
Tenofovir—Infestation—Docetaxel—ovarian cancer	0.000153	0.00253	CcSEcCtD
Tenofovir—Infestation NOS—Docetaxel—ovarian cancer	0.000153	0.00253	CcSEcCtD
Tenofovir—Dyspnoea—Vinorelbine—ovarian cancer	0.000152	0.00252	CcSEcCtD
Tenofovir—ABCC10—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.00015	0.00346	CbGpPWpGaD
Tenofovir—Renal failure—Docetaxel—ovarian cancer	0.00015	0.00248	CcSEcCtD
Tenofovir—Neuropathy peripheral—Docetaxel—ovarian cancer	0.00015	0.00248	CcSEcCtD
Tenofovir—Decreased appetite—Vinorelbine—ovarian cancer	0.000148	0.00246	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000148	0.00341	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000148	0.00341	CbGpPWpGaD
Tenofovir—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000147	0.00244	CcSEcCtD
Tenofovir—Fatigue—Vinorelbine—ovarian cancer	0.000147	0.00244	CcSEcCtD
Tenofovir—Hypersensitivity—Topotecan—ovarian cancer	0.000147	0.00244	CcSEcCtD
Tenofovir—AK2—Metabolism—CYTB—ovarian cancer	0.000146	0.00336	CbGpPWpGaD
Tenofovir—Pain—Vinorelbine—ovarian cancer	0.000146	0.00242	CcSEcCtD
Tenofovir—Immune system disorder—Paclitaxel—ovarian cancer	0.000146	0.00242	CcSEcCtD
Tenofovir—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000146	0.00241	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000145	0.00335	CbGpPWpGaD
Tenofovir—Renal failure acute—Epirubicin—ovarian cancer	0.000145	0.0024	CcSEcCtD
Tenofovir—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000144	0.00239	CcSEcCtD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—MMP9—ovarian cancer	0.000144	0.00331	CbGpPWpGaD
Tenofovir—Hypersensitivity—Melphalan—ovarian cancer	0.000144	0.00238	CcSEcCtD
Tenofovir—Asthenia—Topotecan—ovarian cancer	0.000143	0.00237	CcSEcCtD
Tenofovir—Vomiting—Chlorambucil—ovarian cancer	0.000143	0.00236	CcSEcCtD
Tenofovir—Mental disorder—Paclitaxel—ovarian cancer	0.000142	0.00235	CcSEcCtD
Tenofovir—Pruritus—Topotecan—ovarian cancer	0.000141	0.00234	CcSEcCtD
Tenofovir—CYP1A2—Estrogen metabolism—CYP1B1—ovarian cancer	0.000141	0.00324	CbGpPWpGaD
Tenofovir—Malnutrition—Paclitaxel—ovarian cancer	0.000141	0.00233	CcSEcCtD
Tenofovir—Renal impairment—Epirubicin—ovarian cancer	0.00014	0.00232	CcSEcCtD
Tenofovir—Asthenia—Melphalan—ovarian cancer	0.00014	0.00232	CcSEcCtD
Tenofovir—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00014	0.00231	CcSEcCtD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—HRAS—ovarian cancer	0.000139	0.0032	CbGpPWpGaD
Tenofovir—Flatulence—Paclitaxel—ovarian cancer	0.000139	0.0023	CcSEcCtD
Tenofovir—Pruritus—Melphalan—ovarian cancer	0.000138	0.00229	CcSEcCtD
Tenofovir—Hepatitis—Docetaxel—ovarian cancer	0.000137	0.00227	CcSEcCtD
Tenofovir—Diarrhoea—Topotecan—ovarian cancer	0.000137	0.00226	CcSEcCtD
Tenofovir—Back pain—Paclitaxel—ovarian cancer	0.000136	0.00225	CcSEcCtD
Tenofovir—Urinary tract disorder—Docetaxel—ovarian cancer	0.000135	0.00224	CcSEcCtD
Tenofovir—Body temperature increased—Vinorelbine—ovarian cancer	0.000135	0.00224	CcSEcCtD
Tenofovir—Abdominal pain—Vinorelbine—ovarian cancer	0.000135	0.00224	CcSEcCtD
Tenofovir—Connective tissue disorder—Docetaxel—ovarian cancer	0.000135	0.00223	CcSEcCtD
Tenofovir—Urethral disorder—Docetaxel—ovarian cancer	0.000134	0.00222	CcSEcCtD
Tenofovir—Renal failure acute—Doxorubicin—ovarian cancer	0.000134	0.00222	CcSEcCtD
Tenofovir—Diarrhoea—Melphalan—ovarian cancer	0.000134	0.00221	CcSEcCtD
Tenofovir—Nausea—Chlorambucil—ovarian cancer	0.000133	0.00221	CcSEcCtD
Tenofovir—ABCC4—Ectoderm Differentiation—HDAC6—ovarian cancer	0.000133	0.00306	CbGpPWpGaD
Tenofovir—Dizziness—Topotecan—ovarian cancer	0.000132	0.00219	CcSEcCtD
Tenofovir—Renal impairment—Doxorubicin—ovarian cancer	0.00013	0.00215	CcSEcCtD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—TP53—ovarian cancer	0.000129	0.00297	CbGpPWpGaD
Tenofovir—Angioedema—Paclitaxel—ovarian cancer	0.000129	0.00213	CcSEcCtD
Tenofovir—AK2—Metabolism—PPP1CC—ovarian cancer	0.000128	0.00294	CbGpPWpGaD
Tenofovir—AK2—Metabolism—BRIP1—ovarian cancer	0.000128	0.00294	CbGpPWpGaD
Tenofovir—Vomiting—Topotecan—ovarian cancer	0.000127	0.0021	CcSEcCtD
Tenofovir—Rash—Topotecan—ovarian cancer	0.000126	0.00208	CcSEcCtD
Tenofovir—Hypersensitivity—Vinorelbine—ovarian cancer	0.000126	0.00208	CcSEcCtD
Tenofovir—Dermatitis—Topotecan—ovarian cancer	0.000126	0.00208	CcSEcCtD
Tenofovir—Blood creatinine increased—Epirubicin—ovarian cancer	0.000125	0.00207	CcSEcCtD
Tenofovir—Headache—Topotecan—ovarian cancer	0.000125	0.00207	CcSEcCtD
Tenofovir—CYP1A2—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000125	0.00287	CbGpPWpGaD
Tenofovir—Vomiting—Melphalan—ovarian cancer	0.000124	0.00206	CcSEcCtD
Tenofovir—Immune system disorder—Docetaxel—ovarian cancer	0.000124	0.00205	CcSEcCtD
Tenofovir—Mediastinal disorder—Docetaxel—ovarian cancer	0.000123	0.00205	CcSEcCtD
Tenofovir—Rash—Melphalan—ovarian cancer	0.000123	0.00204	CcSEcCtD
Tenofovir—Dermatitis—Melphalan—ovarian cancer	0.000123	0.00204	CcSEcCtD
Tenofovir—Asthenia—Vinorelbine—ovarian cancer	0.000122	0.00203	CcSEcCtD
Tenofovir—Hypokalaemia—Epirubicin—ovarian cancer	0.000122	0.00201	CcSEcCtD
Tenofovir—Pruritus—Vinorelbine—ovarian cancer	0.000121	0.002	CcSEcCtD
Tenofovir—ABCC4—Platelet degranulation—SOD1—ovarian cancer	0.00012	0.00277	CbGpPWpGaD
Tenofovir—Mental disorder—Docetaxel—ovarian cancer	0.00012	0.00199	CcSEcCtD
Tenofovir—Arthralgia—Paclitaxel—ovarian cancer	0.00012	0.00198	CcSEcCtD
Tenofovir—Myalgia—Paclitaxel—ovarian cancer	0.00012	0.00198	CcSEcCtD
Tenofovir—Chest pain—Paclitaxel—ovarian cancer	0.00012	0.00198	CcSEcCtD
Tenofovir—Nasopharyngitis—Epirubicin—ovarian cancer	0.000119	0.00198	CcSEcCtD
Tenofovir—Anxiety—Paclitaxel—ovarian cancer	0.000119	0.00198	CcSEcCtD
Tenofovir—NME1—Metabolism—NME2—ovarian cancer	0.000119	0.00274	CbGpPWpGaD
Tenofovir—Malnutrition—Docetaxel—ovarian cancer	0.000119	0.00198	CcSEcCtD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—MYC—ovarian cancer	0.000119	0.00274	CbGpPWpGaD
Tenofovir—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000119	0.00197	CcSEcCtD
Tenofovir—ABCC10—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.000119	0.00273	CbGpPWpGaD
Tenofovir—Nausea—Topotecan—ovarian cancer	0.000119	0.00196	CcSEcCtD
Tenofovir—Muscular weakness—Epirubicin—ovarian cancer	0.000118	0.00195	CcSEcCtD
Tenofovir—Diarrhoea—Vinorelbine—ovarian cancer	0.000117	0.00193	CcSEcCtD
Tenofovir—Nausea—Melphalan—ovarian cancer	0.000116	0.00192	CcSEcCtD
Tenofovir—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000116	0.00192	CcSEcCtD
Tenofovir—Back pain—Docetaxel—ovarian cancer	0.000115	0.00191	CcSEcCtD
Tenofovir—CYP1A2—Estrogen Receptor Pathway—ESR1—ovarian cancer	0.000115	0.00264	CbGpPWpGaD
Tenofovir—ABCC4—Response to elevated platelet cytosolic Ca2+—SOD1—ovarian cancer	0.000115	0.00264	CbGpPWpGaD
Tenofovir—Pancreatitis—Epirubicin—ovarian cancer	0.000113	0.00187	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000113	0.0026	CbGpPWpGaD
Tenofovir—Dizziness—Vinorelbine—ovarian cancer	0.000113	0.00187	CcSEcCtD
Tenofovir—Nervous system disorder—Paclitaxel—ovarian cancer	0.000113	0.00187	CcSEcCtD
Tenofovir—Hypokalaemia—Doxorubicin—ovarian cancer	0.000112	0.00186	CcSEcCtD
Tenofovir—Skin disorder—Paclitaxel—ovarian cancer	0.000112	0.00185	CcSEcCtD
Tenofovir—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000111	0.00184	CcSEcCtD
Tenofovir—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000111	0.00183	CcSEcCtD
Tenofovir—Anorexia—Paclitaxel—ovarian cancer	0.000109	0.00181	CcSEcCtD
Tenofovir—Muscular weakness—Doxorubicin—ovarian cancer	0.000109	0.00181	CcSEcCtD
Tenofovir—Vomiting—Vinorelbine—ovarian cancer	0.000109	0.0018	CcSEcCtD
Tenofovir—Rash—Vinorelbine—ovarian cancer	0.000108	0.00178	CcSEcCtD
Tenofovir—Dermatitis—Vinorelbine—ovarian cancer	0.000108	0.00178	CcSEcCtD
Tenofovir—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000107	0.00178	CcSEcCtD
Tenofovir—Headache—Vinorelbine—ovarian cancer	0.000107	0.00177	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000107	0.00246	CbGpPWpGaD
Tenofovir—Pancreatitis—Doxorubicin—ovarian cancer	0.000105	0.00173	CcSEcCtD
Tenofovir—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000105	0.00173	CcSEcCtD
Tenofovir—Weight decreased—Epirubicin—ovarian cancer	0.000104	0.00173	CcSEcCtD
Tenofovir—Hyperglycaemia—Epirubicin—ovarian cancer	0.000104	0.00173	CcSEcCtD
Tenofovir—Insomnia—Paclitaxel—ovarian cancer	0.000104	0.00172	CcSEcCtD
Tenofovir—Pneumonia—Epirubicin—ovarian cancer	0.000104	0.00171	CcSEcCtD
Tenofovir—Infestation NOS—Epirubicin—ovarian cancer	0.000103	0.00171	CcSEcCtD
Tenofovir—Infestation—Epirubicin—ovarian cancer	0.000103	0.00171	CcSEcCtD
Tenofovir—Dyspnoea—Paclitaxel—ovarian cancer	0.000102	0.0017	CcSEcCtD
Tenofovir—Myalgia—Docetaxel—ovarian cancer	0.000102	0.00168	CcSEcCtD
Tenofovir—Arthralgia—Docetaxel—ovarian cancer	0.000102	0.00168	CcSEcCtD
Tenofovir—Chest pain—Docetaxel—ovarian cancer	0.000102	0.00168	CcSEcCtD
Tenofovir—NME2—Metabolism—CYTB—ovarian cancer	0.000101	0.00233	CbGpPWpGaD
Tenofovir—Nausea—Vinorelbine—ovarian cancer	0.000101	0.00168	CcSEcCtD
Tenofovir—Renal failure—Epirubicin—ovarian cancer	0.000101	0.00168	CcSEcCtD
Tenofovir—Dyspepsia—Paclitaxel—ovarian cancer	0.000101	0.00167	CcSEcCtD
Tenofovir—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000101	0.00167	CcSEcCtD
Tenofovir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000101	0.00167	CcSEcCtD
Tenofovir—Decreased appetite—Paclitaxel—ovarian cancer	9.98e-05	0.00165	CcSEcCtD
Tenofovir—Upper respiratory tract infection—Doxorubicin—ovarian cancer	9.93e-05	0.00164	CcSEcCtD
Tenofovir—Gastrointestinal disorder—Paclitaxel—ovarian cancer	9.91e-05	0.00164	CcSEcCtD
Tenofovir—Fatigue—Paclitaxel—ovarian cancer	9.9e-05	0.00164	CcSEcCtD
Tenofovir—Sweating—Epirubicin—ovarian cancer	9.87e-05	0.00163	CcSEcCtD
Tenofovir—Pain—Paclitaxel—ovarian cancer	9.82e-05	0.00163	CcSEcCtD
Tenofovir—Haematuria—Epirubicin—ovarian cancer	9.82e-05	0.00163	CcSEcCtD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—TP53—ovarian cancer	9.78e-05	0.00225	CbGpPWpGaD
Tenofovir—Hepatobiliary disease—Epirubicin—ovarian cancer	9.74e-05	0.00161	CcSEcCtD
Tenofovir—Weight decreased—Doxorubicin—ovarian cancer	9.66e-05	0.0016	CcSEcCtD
Tenofovir—Sinusitis—Epirubicin—ovarian cancer	9.66e-05	0.0016	CcSEcCtD
Tenofovir—Hyperglycaemia—Doxorubicin—ovarian cancer	9.64e-05	0.0016	CcSEcCtD
Tenofovir—CYP1A2—Melatonin metabolism and effects—CYP1B1—ovarian cancer	9.63e-05	0.00221	CbGpPWpGaD
Tenofovir—Pneumonia—Doxorubicin—ovarian cancer	9.58e-05	0.00159	CcSEcCtD
Tenofovir—Nervous system disorder—Docetaxel—ovarian cancer	9.55e-05	0.00158	CcSEcCtD
Tenofovir—Infestation—Doxorubicin—ovarian cancer	9.52e-05	0.00158	CcSEcCtD
Tenofovir—Infestation NOS—Doxorubicin—ovarian cancer	9.52e-05	0.00158	CcSEcCtD
Tenofovir—Skin disorder—Docetaxel—ovarian cancer	9.45e-05	0.00157	CcSEcCtD
Tenofovir—Gastrointestinal pain—Paclitaxel—ovarian cancer	9.39e-05	0.00156	CcSEcCtD
Tenofovir—Renal failure—Doxorubicin—ovarian cancer	9.36e-05	0.00155	CcSEcCtD
Tenofovir—Neuropathy peripheral—Doxorubicin—ovarian cancer	9.34e-05	0.00155	CcSEcCtD
Tenofovir—Anorexia—Docetaxel—ovarian cancer	9.28e-05	0.00154	CcSEcCtD
Tenofovir—Hepatitis—Epirubicin—ovarian cancer	9.24e-05	0.00153	CcSEcCtD
Tenofovir—Sweating—Doxorubicin—ovarian cancer	9.13e-05	0.00151	CcSEcCtD
Tenofovir—Urinary tract disorder—Epirubicin—ovarian cancer	9.13e-05	0.00151	CcSEcCtD
Tenofovir—Haematuria—Doxorubicin—ovarian cancer	9.08e-05	0.0015	CcSEcCtD
Tenofovir—Connective tissue disorder—Epirubicin—ovarian cancer	9.08e-05	0.0015	CcSEcCtD
Tenofovir—Abdominal pain—Paclitaxel—ovarian cancer	9.08e-05	0.0015	CcSEcCtD
Tenofovir—Body temperature increased—Paclitaxel—ovarian cancer	9.08e-05	0.0015	CcSEcCtD
Tenofovir—Urethral disorder—Epirubicin—ovarian cancer	9.06e-05	0.0015	CcSEcCtD
Tenofovir—ABCC4—NRF2 pathway—SLC5A5—ovarian cancer	9.02e-05	0.00207	CbGpPWpGaD
Tenofovir—Hepatobiliary disease—Doxorubicin—ovarian cancer	9.01e-05	0.00149	CcSEcCtD
Tenofovir—Sinusitis—Doxorubicin—ovarian cancer	8.94e-05	0.00148	CcSEcCtD
Tenofovir—Musculoskeletal discomfort—Docetaxel—ovarian cancer	8.87e-05	0.00147	CcSEcCtD
Tenofovir—NME2—Metabolism—PPP1CC—ovarian cancer	8.86e-05	0.00204	CbGpPWpGaD
Tenofovir—NME2—Metabolism—BRIP1—ovarian cancer	8.86e-05	0.00204	CbGpPWpGaD
Tenofovir—Insomnia—Docetaxel—ovarian cancer	8.8e-05	0.00146	CcSEcCtD
Tenofovir—ABCC4—NRF2 pathway—SLC2A1—ovarian cancer	8.71e-05	0.002	CbGpPWpGaD
Tenofovir—Dyspnoea—Docetaxel—ovarian cancer	8.68e-05	0.00144	CcSEcCtD
Tenofovir—AK2—Metabolism—YAP1—ovarian cancer	8.58e-05	0.00197	CbGpPWpGaD
Tenofovir—Dyspepsia—Docetaxel—ovarian cancer	8.57e-05	0.00142	CcSEcCtD
Tenofovir—Hepatitis—Doxorubicin—ovarian cancer	8.55e-05	0.00142	CcSEcCtD
Tenofovir—Decreased appetite—Docetaxel—ovarian cancer	8.46e-05	0.0014	CcSEcCtD
Tenofovir—Hypersensitivity—Paclitaxel—ovarian cancer	8.46e-05	0.0014	CcSEcCtD
Tenofovir—Urinary tract disorder—Doxorubicin—ovarian cancer	8.44e-05	0.0014	CcSEcCtD
Tenofovir—Gastrointestinal disorder—Docetaxel—ovarian cancer	8.4e-05	0.00139	CcSEcCtD
Tenofovir—Connective tissue disorder—Doxorubicin—ovarian cancer	8.4e-05	0.00139	CcSEcCtD
Tenofovir—Fatigue—Docetaxel—ovarian cancer	8.39e-05	0.00139	CcSEcCtD
Tenofovir—Urethral disorder—Doxorubicin—ovarian cancer	8.38e-05	0.00139	CcSEcCtD
Tenofovir—Immune system disorder—Epirubicin—ovarian cancer	8.35e-05	0.00138	CcSEcCtD
Tenofovir—Mediastinal disorder—Epirubicin—ovarian cancer	8.33e-05	0.00138	CcSEcCtD
Tenofovir—Pain—Docetaxel—ovarian cancer	8.32e-05	0.00138	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	8.29e-05	0.00191	CbGpPWpGaD
Tenofovir—Asthenia—Paclitaxel—ovarian cancer	8.24e-05	0.00136	CcSEcCtD
Tenofovir—Pruritus—Paclitaxel—ovarian cancer	8.12e-05	0.00135	CcSEcCtD
Tenofovir—Mental disorder—Epirubicin—ovarian cancer	8.1e-05	0.00134	CcSEcCtD
Tenofovir—Malnutrition—Epirubicin—ovarian cancer	8.04e-05	0.00133	CcSEcCtD
Tenofovir—Gastrointestinal pain—Docetaxel—ovarian cancer	7.96e-05	0.00132	CcSEcCtD
Tenofovir—ABCC10—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	7.93e-05	0.00182	CbGpPWpGaD
Tenofovir—Flatulence—Epirubicin—ovarian cancer	7.93e-05	0.00131	CcSEcCtD
Tenofovir—Diarrhoea—Paclitaxel—ovarian cancer	7.86e-05	0.0013	CcSEcCtD
Tenofovir—Back pain—Epirubicin—ovarian cancer	7.78e-05	0.00129	CcSEcCtD
Tenofovir—Immune system disorder—Doxorubicin—ovarian cancer	7.72e-05	0.00128	CcSEcCtD
Tenofovir—Mediastinal disorder—Doxorubicin—ovarian cancer	7.71e-05	0.00128	CcSEcCtD
Tenofovir—Body temperature increased—Docetaxel—ovarian cancer	7.69e-05	0.00127	CcSEcCtD
Tenofovir—Abdominal pain—Docetaxel—ovarian cancer	7.69e-05	0.00127	CcSEcCtD
Tenofovir—NME1—Metabolism—CYTB—ovarian cancer	7.69e-05	0.00177	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	7.68e-05	0.00177	CbGpPWpGaD
Tenofovir—ABCC10—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	7.66e-05	0.00176	CbGpPWpGaD
Tenofovir—ABCC2—NRF2 pathway—SLC5A5—ovarian cancer	7.6e-05	0.00175	CbGpPWpGaD
Tenofovir—Dizziness—Paclitaxel—ovarian cancer	7.59e-05	0.00126	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	7.53e-05	0.00173	CbGpPWpGaD
Tenofovir—Mental disorder—Doxorubicin—ovarian cancer	7.49e-05	0.00124	CcSEcCtD
Tenofovir—Malnutrition—Doxorubicin—ovarian cancer	7.44e-05	0.00123	CcSEcCtD
Tenofovir—ABCC4—Fluoropyrimidine Activity—TP53—ovarian cancer	7.36e-05	0.00169	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—SPARC—ovarian cancer	7.35e-05	0.00169	CbGpPWpGaD
Tenofovir—ABCC2—NRF2 pathway—SLC2A1—ovarian cancer	7.34e-05	0.00169	CbGpPWpGaD
Tenofovir—Flatulence—Doxorubicin—ovarian cancer	7.33e-05	0.00121	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	7.33e-05	0.00168	CbGpPWpGaD
Tenofovir—Vomiting—Paclitaxel—ovarian cancer	7.3e-05	0.00121	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	7.25e-05	0.00167	CbGpPWpGaD
Tenofovir—Rash—Paclitaxel—ovarian cancer	7.24e-05	0.0012	CcSEcCtD
Tenofovir—Dermatitis—Paclitaxel—ovarian cancer	7.23e-05	0.0012	CcSEcCtD
Tenofovir—Back pain—Doxorubicin—ovarian cancer	7.2e-05	0.00119	CcSEcCtD
Tenofovir—Headache—Paclitaxel—ovarian cancer	7.19e-05	0.00119	CcSEcCtD
Tenofovir—Hypersensitivity—Docetaxel—ovarian cancer	7.17e-05	0.00119	CcSEcCtD
Tenofovir—ABCC4—Hemostasis—RAD51C—ovarian cancer	7.1e-05	0.00163	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	7.07e-05	0.00163	CbGpPWpGaD
Tenofovir—AK2—Metabolism—FASN—ovarian cancer	6.99e-05	0.00161	CbGpPWpGaD
Tenofovir—Asthenia—Docetaxel—ovarian cancer	6.98e-05	0.00116	CcSEcCtD
Tenofovir—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	6.98e-05	0.00161	CbGpPWpGaD
Tenofovir—Pruritus—Docetaxel—ovarian cancer	6.89e-05	0.00114	CcSEcCtD
Tenofovir—AK2—Metabolism—SLC5A5—ovarian cancer	6.88e-05	0.00158	CbGpPWpGaD
Tenofovir—Arthralgia—Epirubicin—ovarian cancer	6.85e-05	0.00113	CcSEcCtD
Tenofovir—Chest pain—Epirubicin—ovarian cancer	6.85e-05	0.00113	CcSEcCtD
Tenofovir—Myalgia—Epirubicin—ovarian cancer	6.85e-05	0.00113	CcSEcCtD
Tenofovir—Anxiety—Epirubicin—ovarian cancer	6.83e-05	0.00113	CcSEcCtD
Tenofovir—Nausea—Paclitaxel—ovarian cancer	6.82e-05	0.00113	CcSEcCtD
Tenofovir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	6.8e-05	0.00113	CcSEcCtD
Tenofovir—NME1—Metabolism—BRIP1—ovarian cancer	6.72e-05	0.00154	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PPP1CC—ovarian cancer	6.72e-05	0.00154	CbGpPWpGaD
Tenofovir—Diarrhoea—Docetaxel—ovarian cancer	6.66e-05	0.0011	CcSEcCtD
Tenofovir—CYP1A2—Tryptophan metabolism—CYP1B1—ovarian cancer	6.66e-05	0.00153	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	6.66e-05	0.00153	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	6.66e-05	0.00153	CbGpPWpGaD
Tenofovir—AK2—Metabolism—SLC2A1—ovarian cancer	6.64e-05	0.00153	CbGpPWpGaD
Tenofovir—Nervous system disorder—Epirubicin—ovarian cancer	6.44e-05	0.00107	CcSEcCtD
Tenofovir—Dizziness—Docetaxel—ovarian cancer	6.44e-05	0.00107	CcSEcCtD
Tenofovir—CYP1A2—Estrogen Receptor Pathway—STAT3—ovarian cancer	6.43e-05	0.00148	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	6.39e-05	0.00147	CbGpPWpGaD
Tenofovir—Skin disorder—Epirubicin—ovarian cancer	6.38e-05	0.00106	CcSEcCtD
Tenofovir—AK2—Metabolism—CYP1B1—ovarian cancer	6.37e-05	0.00146	CbGpPWpGaD
Tenofovir—Hyperhidrosis—Epirubicin—ovarian cancer	6.35e-05	0.00105	CcSEcCtD
Tenofovir—Arthralgia—Doxorubicin—ovarian cancer	6.34e-05	0.00105	CcSEcCtD
Tenofovir—Chest pain—Doxorubicin—ovarian cancer	6.34e-05	0.00105	CcSEcCtD
Tenofovir—Myalgia—Doxorubicin—ovarian cancer	6.34e-05	0.00105	CcSEcCtD
Tenofovir—Anxiety—Doxorubicin—ovarian cancer	6.32e-05	0.00105	CcSEcCtD
Tenofovir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.29e-05	0.00104	CcSEcCtD
Tenofovir—Anorexia—Epirubicin—ovarian cancer	6.26e-05	0.00104	CcSEcCtD
Tenofovir—CYP1A2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	6.23e-05	0.00143	CbGpPWpGaD
Tenofovir—Vomiting—Docetaxel—ovarian cancer	6.19e-05	0.00103	CcSEcCtD
Tenofovir—Rash—Docetaxel—ovarian cancer	6.14e-05	0.00102	CcSEcCtD
Tenofovir—Dermatitis—Docetaxel—ovarian cancer	6.13e-05	0.00102	CcSEcCtD
Tenofovir—Headache—Docetaxel—ovarian cancer	6.1e-05	0.00101	CcSEcCtD
Tenofovir—ABCC10—Transmembrane transport of small molecules—ABCB1—ovarian cancer	6.05e-05	0.00139	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	6.04e-05	0.00139	CbGpPWpGaD
Tenofovir—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.98e-05	0.000991	CcSEcCtD
Tenofovir—Nervous system disorder—Doxorubicin—ovarian cancer	5.96e-05	0.000987	CcSEcCtD
Tenofovir—SLC22A8—Transmembrane transport of small molecules—AQP3—ovarian cancer	5.96e-05	0.00137	CbGpPWpGaD
Tenofovir—NME2—Metabolism—YAP1—ovarian cancer	5.95e-05	0.00137	CbGpPWpGaD
Tenofovir—Insomnia—Epirubicin—ovarian cancer	5.94e-05	0.000984	CcSEcCtD
Tenofovir—SLC22A8—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	5.93e-05	0.00136	CbGpPWpGaD
Tenofovir—Skin disorder—Doxorubicin—ovarian cancer	5.9e-05	0.000977	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	5.88e-05	0.00135	CbGpPWpGaD
Tenofovir—Hyperhidrosis—Doxorubicin—ovarian cancer	5.87e-05	0.000973	CcSEcCtD
Tenofovir—Dyspnoea—Epirubicin—ovarian cancer	5.85e-05	0.00097	CcSEcCtD
Tenofovir—Anorexia—Doxorubicin—ovarian cancer	5.79e-05	0.000959	CcSEcCtD
Tenofovir—Nausea—Docetaxel—ovarian cancer	5.78e-05	0.000958	CcSEcCtD
Tenofovir—Dyspepsia—Epirubicin—ovarian cancer	5.78e-05	0.000957	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	5.75e-05	0.00132	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	5.75e-05	0.00132	CbGpPWpGaD
Tenofovir—SLC22A8—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	5.72e-05	0.00132	CbGpPWpGaD
Tenofovir—ABCC4—Transmembrane transport of small molecules—AQP3—ovarian cancer	5.71e-05	0.00131	CbGpPWpGaD
Tenofovir—SLC22A8—Transmembrane transport of small molecules—ATP7B—ovarian cancer	5.71e-05	0.00131	CbGpPWpGaD
Tenofovir—Decreased appetite—Epirubicin—ovarian cancer	5.71e-05	0.000945	CcSEcCtD
Tenofovir—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.67e-05	0.000939	CcSEcCtD
Tenofovir—Fatigue—Epirubicin—ovarian cancer	5.66e-05	0.000938	CcSEcCtD
Tenofovir—AK2—Metabolism—PPP2R1A—ovarian cancer	5.65e-05	0.0013	CbGpPWpGaD
Tenofovir—Pain—Epirubicin—ovarian cancer	5.61e-05	0.00093	CcSEcCtD
Tenofovir—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	5.53e-05	0.000917	CcSEcCtD
Tenofovir—Insomnia—Doxorubicin—ovarian cancer	5.49e-05	0.00091	CcSEcCtD
Tenofovir—ABCC4—Transmembrane transport of small molecules—ATP7B—ovarian cancer	5.47e-05	0.00126	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	5.43e-05	0.00125	CbGpPWpGaD
Tenofovir—Dyspnoea—Doxorubicin—ovarian cancer	5.42e-05	0.000897	CcSEcCtD
Tenofovir—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	5.38e-05	0.00124	CbGpPWpGaD
Tenofovir—Gastrointestinal pain—Epirubicin—ovarian cancer	5.37e-05	0.000889	CcSEcCtD
Tenofovir—Dyspepsia—Doxorubicin—ovarian cancer	5.35e-05	0.000886	CcSEcCtD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—SOD1—ovarian cancer	5.34e-05	0.00123	CbGpPWpGaD
Tenofovir—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	5.31e-05	0.00122	CbGpPWpGaD
Tenofovir—Decreased appetite—Doxorubicin—ovarian cancer	5.28e-05	0.000875	CcSEcCtD
Tenofovir—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.24e-05	0.000869	CcSEcCtD
Tenofovir—AK2—Metabolism—ABCB1—ovarian cancer	5.24e-05	0.00121	CbGpPWpGaD
Tenofovir—Fatigue—Doxorubicin—ovarian cancer	5.24e-05	0.000867	CcSEcCtD
Tenofovir—Pain—Doxorubicin—ovarian cancer	5.19e-05	0.00086	CcSEcCtD
Tenofovir—Abdominal pain—Epirubicin—ovarian cancer	5.19e-05	0.00086	CcSEcCtD
Tenofovir—Body temperature increased—Epirubicin—ovarian cancer	5.19e-05	0.00086	CcSEcCtD
Tenofovir—Adenosine triphosphate—ABCB1—ovarian cancer	5.16e-05	0.0122	CrCbGaD
Tenofovir—AK2—Metabolism—TYMS—ovarian cancer	5.15e-05	0.00118	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	4.99e-05	0.00115	CbGpPWpGaD
Tenofovir—SLC22A6—Transmembrane transport of small molecules—AQP3—ovarian cancer	4.97e-05	0.00114	CbGpPWpGaD
Tenofovir—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.97e-05	0.000823	CcSEcCtD
Tenofovir—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	4.95e-05	0.00114	CbGpPWpGaD
Tenofovir—NME2—Metabolism—FASN—ovarian cancer	4.85e-05	0.00111	CbGpPWpGaD
Tenofovir—Hypersensitivity—Epirubicin—ovarian cancer	4.84e-05	0.000801	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	4.83e-05	0.00111	CbGpPWpGaD
Tenofovir—ABCC2—Transmembrane transport of small molecules—AQP3—ovarian cancer	4.82e-05	0.00111	CbGpPWpGaD
Tenofovir—Abdominal pain—Doxorubicin—ovarian cancer	4.8e-05	0.000795	CcSEcCtD
Tenofovir—Body temperature increased—Doxorubicin—ovarian cancer	4.8e-05	0.000795	CcSEcCtD
Tenofovir—ABCC4—Platelet degranulation—VEGFA—ovarian cancer	4.8e-05	0.0011	CbGpPWpGaD
Tenofovir—SLC22A6—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	4.78e-05	0.0011	CbGpPWpGaD
Tenofovir—NME2—Metabolism—SLC5A5—ovarian cancer	4.77e-05	0.0011	CbGpPWpGaD
Tenofovir—SLC22A6—Transmembrane transport of small molecules—ATP7B—ovarian cancer	4.77e-05	0.0011	CbGpPWpGaD
Tenofovir—Asthenia—Epirubicin—ovarian cancer	4.71e-05	0.00078	CcSEcCtD
Tenofovir—Pruritus—Epirubicin—ovarian cancer	4.64e-05	0.000769	CcSEcCtD
Tenofovir—ABCC2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	4.62e-05	0.00106	CbGpPWpGaD
Tenofovir—NME2—Metabolism—SLC2A1—ovarian cancer	4.6e-05	0.00106	CbGpPWpGaD
Tenofovir—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—ovarian cancer	4.57e-05	0.00105	CbGpPWpGaD
Tenofovir—SLC22A8—Transmembrane transport of small molecules—TUBB3—ovarian cancer	4.51e-05	0.00104	CbGpPWpGaD
Tenofovir—NME1—Metabolism—YAP1—ovarian cancer	4.51e-05	0.00104	CbGpPWpGaD
Tenofovir—Diarrhoea—Epirubicin—ovarian cancer	4.49e-05	0.000744	CcSEcCtD
Tenofovir—Hypersensitivity—Doxorubicin—ovarian cancer	4.48e-05	0.000741	CcSEcCtD
Tenofovir—NME2—Metabolism—CYP1B1—ovarian cancer	4.41e-05	0.00102	CbGpPWpGaD
Tenofovir—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	4.36e-05	0.001	CbGpPWpGaD
Tenofovir—Asthenia—Doxorubicin—ovarian cancer	4.36e-05	0.000722	CcSEcCtD
Tenofovir—Dizziness—Epirubicin—ovarian cancer	4.34e-05	0.000719	CcSEcCtD
Tenofovir—ABCC4—Transmembrane transport of small molecules—TUBB3—ovarian cancer	4.33e-05	0.000995	CbGpPWpGaD
Tenofovir—Pruritus—Doxorubicin—ovarian cancer	4.3e-05	0.000712	CcSEcCtD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	4.18e-05	0.000961	CbGpPWpGaD
Tenofovir—Vomiting—Epirubicin—ovarian cancer	4.17e-05	0.000691	CcSEcCtD
Tenofovir—Diarrhoea—Doxorubicin—ovarian cancer	4.16e-05	0.000688	CcSEcCtD
Tenofovir—AK2—Metabolism—CAV1—ovarian cancer	4.15e-05	0.000954	CbGpPWpGaD
Tenofovir—Rash—Epirubicin—ovarian cancer	4.14e-05	0.000686	CcSEcCtD
Tenofovir—Dermatitis—Epirubicin—ovarian cancer	4.14e-05	0.000685	CcSEcCtD
Tenofovir—Headache—Epirubicin—ovarian cancer	4.11e-05	0.000681	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.07e-05	0.000937	CbGpPWpGaD
Tenofovir—Dizziness—Doxorubicin—ovarian cancer	4.02e-05	0.000665	CcSEcCtD
Tenofovir—NME2—Metabolism—PPP2R1A—ovarian cancer	3.92e-05	0.0009	CbGpPWpGaD
Tenofovir—Nausea—Epirubicin—ovarian cancer	3.9e-05	0.000646	CcSEcCtD
Tenofovir—Vomiting—Doxorubicin—ovarian cancer	3.86e-05	0.00064	CcSEcCtD
Tenofovir—Rash—Doxorubicin—ovarian cancer	3.83e-05	0.000634	CcSEcCtD
Tenofovir—Dermatitis—Doxorubicin—ovarian cancer	3.83e-05	0.000634	CcSEcCtD
Tenofovir—Headache—Doxorubicin—ovarian cancer	3.81e-05	0.00063	CcSEcCtD
Tenofovir—ABCC4—Hemostasis—SPARC—ovarian cancer	3.79e-05	0.000871	CbGpPWpGaD
Tenofovir—AK2—Metabolism—PIK3CG—ovarian cancer	3.78e-05	0.000869	CbGpPWpGaD
Tenofovir—SLC22A6—Transmembrane transport of small molecules—TUBB3—ovarian cancer	3.77e-05	0.000866	CbGpPWpGaD
Tenofovir—NME1—Metabolism—FASN—ovarian cancer	3.67e-05	0.000845	CbGpPWpGaD
Tenofovir—ABCC2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	3.65e-05	0.000839	CbGpPWpGaD
Tenofovir—NME2—Metabolism—ABCB1—ovarian cancer	3.64e-05	0.000836	CbGpPWpGaD
Tenofovir—NME1—Metabolism—SLC5A5—ovarian cancer	3.61e-05	0.000831	CbGpPWpGaD
Tenofovir—Nausea—Doxorubicin—ovarian cancer	3.61e-05	0.000598	CcSEcCtD
Tenofovir—NME2—Metabolism—TYMS—ovarian cancer	3.57e-05	0.000821	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	3.56e-05	0.000818	CbGpPWpGaD
Tenofovir—ABCC4—Ectoderm Differentiation—CTNNB1—ovarian cancer	3.52e-05	0.00081	CbGpPWpGaD
Tenofovir—NME1—Metabolism—SLC2A1—ovarian cancer	3.49e-05	0.000802	CbGpPWpGaD
Tenofovir—NME1—Metabolism—CYP1B1—ovarian cancer	3.35e-05	0.000769	CbGpPWpGaD
Tenofovir—AK2—Metabolism—PIK3CD—ovarian cancer	3.32e-05	0.000764	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	3.13e-05	0.000719	CbGpPWpGaD
Tenofovir—SLC22A8—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.01e-05	0.000693	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PPP2R1A—ovarian cancer	2.97e-05	0.000682	CbGpPWpGaD
Tenofovir—SLC22A8—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.91e-05	0.000669	CbGpPWpGaD
Tenofovir—AK2—Metabolism—PIK3CB—ovarian cancer	2.9e-05	0.000666	CbGpPWpGaD
Tenofovir—ABCC4—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.89e-05	0.000664	CbGpPWpGaD
Tenofovir—NME2—Metabolism—CAV1—ovarian cancer	2.88e-05	0.000662	CbGpPWpGaD
Tenofovir—ABCC4—Ectoderm Differentiation—MYC—ovarian cancer	2.85e-05	0.000656	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	2.84e-05	0.000653	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	2.84e-05	0.000653	CbGpPWpGaD
Tenofovir—ABCC4—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.79e-05	0.000641	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	2.78e-05	0.000639	CbGpPWpGaD
Tenofovir—NME1—Metabolism—ABCB1—ovarian cancer	2.76e-05	0.000634	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—SOD1—ovarian cancer	2.75e-05	0.000633	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—PPP2R1A—ovarian cancer	2.74e-05	0.00063	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	2.73e-05	0.000627	CbGpPWpGaD
Tenofovir—NME1—Metabolism—TYMS—ovarian cancer	2.71e-05	0.000622	CbGpPWpGaD
Tenofovir—NME2—Metabolism—PIK3CG—ovarian cancer	2.62e-05	0.000603	CbGpPWpGaD
Tenofovir—SLC22A6—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.51e-05	0.000578	CbGpPWpGaD
Tenofovir—AK2—Metabolism—PTEN—ovarian cancer	2.5e-05	0.000576	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—IL2—ovarian cancer	2.5e-05	0.000576	CbGpPWpGaD
Tenofovir—ABCC2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.43e-05	0.00056	CbGpPWpGaD
Tenofovir—SLC22A6—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.43e-05	0.000558	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	2.36e-05	0.000543	CbGpPWpGaD
Tenofovir—ABCC2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.35e-05	0.000541	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	2.33e-05	0.000537	CbGpPWpGaD
Tenofovir—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	2.32e-05	0.000533	CbGpPWpGaD
Tenofovir—NME2—Metabolism—PIK3CD—ovarian cancer	2.3e-05	0.00053	CbGpPWpGaD
Tenofovir—SLC22A8—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.3e-05	0.000528	CbGpPWpGaD
Tenofovir—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	2.29e-05	0.000526	CbGpPWpGaD
Tenofovir—ABCC4—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.2e-05	0.000506	CbGpPWpGaD
Tenofovir—NME1—Metabolism—CAV1—ovarian cancer	2.18e-05	0.000501	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	2.17e-05	0.0005	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	2.13e-05	0.000489	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	2.13e-05	0.000489	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	2.13e-05	0.000489	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	2.13e-05	0.000489	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—CAV1—ovarian cancer	2.01e-05	0.000463	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	2.01e-05	0.000463	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	2.01e-05	0.000462	CbGpPWpGaD
Tenofovir—NME2—Metabolism—PIK3CB—ovarian cancer	2.01e-05	0.000462	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PIK3CG—ovarian cancer	1.99e-05	0.000457	CbGpPWpGaD
Tenofovir—SLC22A6—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.92e-05	0.000441	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	1.91e-05	0.00044	CbGpPWpGaD
Tenofovir—ABCC2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.86e-05	0.000427	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—PIK3CG—ovarian cancer	1.83e-05	0.000422	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	1.79e-05	0.000411	CbGpPWpGaD
Tenofovir—AK2—Metabolism—PIK3CA—ovarian cancer	1.77e-05	0.000406	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PIK3CD—ovarian cancer	1.75e-05	0.000401	CbGpPWpGaD
Tenofovir—NME2—Metabolism—PTEN—ovarian cancer	1.74e-05	0.000399	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	1.71e-05	0.000393	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	1.66e-05	0.000382	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—PIK3CD—ovarian cancer	1.61e-05	0.000371	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PIK3CB—ovarian cancer	1.52e-05	0.00035	CbGpPWpGaD
Tenofovir—AK2—Metabolism—AKT1—ovarian cancer	1.44e-05	0.000332	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—NME2—ovarian cancer	1.41e-05	0.000325	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—PIK3CB—ovarian cancer	1.4e-05	0.000323	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.36e-05	0.000312	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PTEN—ovarian cancer	1.31e-05	0.000302	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—IL2—ovarian cancer	1.29e-05	0.000297	CbGpPWpGaD
Tenofovir—NME2—Metabolism—PIK3CA—ovarian cancer	1.22e-05	0.000281	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.2e-05	0.000276	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—VEGFA—ovarian cancer	1.1e-05	0.000252	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—NRAS—ovarian cancer	1.08e-05	0.000249	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—MAPK3—ovarian cancer	1.04e-05	0.000239	CbGpPWpGaD
Tenofovir—NME2—Metabolism—AKT1—ovarian cancer	1e-05	0.00023	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—MAPK1—ovarian cancer	9.87e-06	0.000227	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	9.77e-06	0.000225	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—KRAS—ovarian cancer	9.32e-06	0.000214	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PIK3CA—ovarian cancer	9.28e-06	0.000213	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—CYTB—ovarian cancer	9.11e-06	0.000209	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	8.9e-06	0.000205	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—PIK3CA—ovarian cancer	8.56e-06	0.000197	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—TP53—ovarian cancer	8.28e-06	0.000191	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PPP1CC—ovarian cancer	7.96e-06	0.000183	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—BRIP1—ovarian cancer	7.96e-06	0.000183	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—HRAS—ovarian cancer	7.92e-06	0.000182	CbGpPWpGaD
Tenofovir—NME1—Metabolism—AKT1—ovarian cancer	7.58e-06	0.000174	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—AKT1—ovarian cancer	7e-06	0.000161	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.8e-06	0.000133	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—YAP1—ovarian cancer	5.34e-06	0.000123	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.28e-06	0.000121	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.64e-06	0.000107	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—FASN—ovarian cancer	4.35e-06	0.0001	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—SLC5A5—ovarian cancer	4.28e-06	9.84e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—SLC2A1—ovarian cancer	4.13e-06	9.51e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.05e-06	9.31e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—CYP1B1—ovarian cancer	3.96e-06	9.11e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	3.52e-06	8.08e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.5e-06	8.04e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—ABCB1—ovarian cancer	3.26e-06	7.51e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—TYMS—ovarian cancer	3.21e-06	7.37e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—CAV1—ovarian cancer	2.58e-06	5.94e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.47e-06	5.67e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.35e-06	5.41e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.07e-06	4.76e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.8e-06	4.15e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PTEN—ovarian cancer	1.56e-06	3.58e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.1e-06	2.53e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—AKT1—ovarian cancer	8.98e-07	2.06e-05	CbGpPWpGaD
